196 related articles for article (PubMed ID: 36894965)
21. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.
Inceman M; Toyran T; Bayazit Y; Izol V; Erdogan S
Pol J Pathol; 2022; 73(3):181-190. PubMed ID: 36734432
[TBL] [Abstract][Full Text] [Related]
22. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
23. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
Mahmoud AM; Frank I; Orme JJ; Lavoie RR; Thapa P; Costello BA; Cheville JC; Gupta S; Dong H; Lucien F
BMC Urol; 2022 Jun; 22(1):90. PubMed ID: 35751046
[TBL] [Abstract][Full Text] [Related]
24. Expression of B7 family checkpoint proteins in cervical cancer.
Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
26. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
27. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Giraldo NA; Becht E; Pagès F; Skliris G; Verkarre V; Vano Y; Mejean A; Saint-Aubert N; Lacroix L; Natario I; Lupo A; Alifano M; Damotte D; Cazes A; Triebel F; Freeman GJ; Dieu-Nosjean MC; Oudard S; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2015 Jul; 21(13):3031-40. PubMed ID: 25688160
[TBL] [Abstract][Full Text] [Related]
28. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
30. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
Sule Kutlar Dursun F; Alabalik U
Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
[TBL] [Abstract][Full Text] [Related]
31. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
33. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
34. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
35. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract][Full Text] [Related]
36. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
39. Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Kammerer-Jacquet SF; Medane S; Bensalah K; Bernhard JC; Yacoub M; Dupuis F; Ravaud A; Verhoest G; Mathieu R; Peyronnet B; Brunot A; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Target Oncol; 2017 Aug; 12(4):487-494. PubMed ID: 28550387
[TBL] [Abstract][Full Text] [Related]
40. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]